
Publisher's PDF, also known as Version of record

License (if available):
CC BY-NC-ND

Link to published version (if available):
10.1016/j.dib.2015.12.051

Link to publication record in Explore Bristol Research
PDF-document

This is the final published version of the article (version of record). It first appeared online via Elsevier at https://doi.org/10.1016/j.dib.2015.12.051. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Data Article

Data supporting the regulation of FOXC2 in podocyte dysfunction

Neeta Datta a, Sonja Lindfors a, Naoyuki Miura b, Moin A. Saleem c, Sanna Lehtonen a,

a Department of Pathology, University of Helsinki, 00290 Helsinki, Finland
b Department of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
c Academic and Children’s Renal Unit, Dorothy Hodgkin Building, Bristol BS1, United Kingdom

ARTICLE INFO

Article history:
Received 15 December 2015
Accepted 30 December 2015
Available online 7 January 2016

ABSTRACT

This data article shows the expression levels of specific podocyte injury markers and podocyte slit diaphragm protein nephrin in obese and lean Zucker rat glomeruli. It also contains information on the effect of the overexpression of transcription factor FOXC2 on the ratio of F- and G-actin and the expression level of ZO-1 in differentiated human podocytes. The article also shows data on the effect of treatments of differentiated podocytes with various factors associated with obesity and diabetes on the expression level of FOXC2. The detailed interpretation of these data and other aspects of podocyte injury mediated by upregulation of FOXC2 can be found in "Overexpression of transcription factor FOXC2 in cultured human podocytes upregulates injury markers and increases motility [1]."

© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Specifications table

<table>
<thead>
<tr>
<th>Subject area</th>
<th>Nephrology</th>
</tr>
</thead>
<tbody>
<tr>
<td>More specific subject area</td>
<td>Obesity-related kidney injury</td>
</tr>
</tbody>
</table>

DOI of original article: http://dx.doi.org/10.1016/j.yexcr.2015.10.035
* Corresponding author.
E-mail address: sanna.h.lehtonen@helsinki.fi (S. Lehtonen).

http://dx.doi.org/10.1016/j.dib.2015.12.051
2352-3409 © 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
### Value of the data

- The obese Zucker rats show a trend towards upregulation of podocyte injury markers in glomeruli.
- The obese Zucker rats with the highest level of proteinuria express least nephrin in glomeruli.
- Overexpression of FOXC2 in differentiated human podocytes in vitro does not change the F-actin/G-actin ratio, or the expression level of the tight junction protein ZO-1.
- Several obesity and diabetes-associated factors were found not to upregulate FOXC2 in differentiated human podocytes.

### 1. Data

Quantitative Western blotting reveals that podocyte injury markers active beta-catenin, desmin and fibronectin show a trend of upregulation in the glomeruli of 40 weeks old obese Zucker rats compared to lean controls (Fig. 1A and B). Nephrin, the key protein of the interpodocyte slit diaphragm, shows a trend of downregulation in the glomeruli of obese rats (Fig. 1C and D), with the most albuminuric rats expressing least nephrin (Fig. 1E). Exposure of differentiated human podocytes to factors associated with obesity, insulin resistance and type 2 diabetes did not increase the expression of FOXC2 as observed by quantitative RT-PCR for tumor necrosis factor-α (TNF-α) and transforming growth factor β (TGF-β) (Fig. 2A and B), and by quantitative Western blotting for angiotensin II and a combination of glucose and palmitate (Fig. 2C-F). The data also show that overexpression of FOXC2 in differentiated human podocytes by lentiviral transduction does not change the ratio of filamentous (F) actin and globular (G) actin (Fig. 3A and B) or the expression level of the tight junction protein ZO-1 (Fig. 4A and B).

### 2. Experimental design, materials and methods

#### 2.1. Animal model and preparation of glomerular lysates

Obese (fa/fa) and lean (fa/+) Zucker rats (Crl:ZUC-Leprfa) were obtained from Charles River Laboratories (Sulzfeld, Germany). Blood glucose values were measured from tail vein samples using OneTouch Ultra glucometer (Lifescan, Milpitas, CA). The urinary albumin to creatinine ratio was determined from spot urine samples. Albumin was measured with rat albumin ELISA kit (CellTrend, Luckenwalde, Germany) and creatinine using CREA plus enzymatic assay (Roche, Basel, Switzerland) and Roche clinical chemistry analyzer (Table 1). The experiments were approved by the National Animal Experiment Board. Glomerular fractions were isolated from 40 weeks old rat kidney cortices.
Fig. 1. Immunoblotting reveals an increasing trend of key podocyte injury markers and decreasing nephrin expression in obese Zucker rat glomerular lysates. (A) 75 μg of glomerular lysates were separated by SDS-PAGE and immunoblotted for active β-catenin, desmin and fibronectin. Actin was used as the loading control. (B) Quantification shows an increasing trend in the expression of active beta-catenin, desmin and fibronectin in the glomeruli of the obese Zucker rats compared to the lean controls (n=5 for lean & n=4 for obese). (C, D) Immunoblotting for nephrin and subsequent quantification shows a decreasing trend in the expression of nephrin in the glomeruli of the obese Zucker rats compared to the lean controls. (n=6 for lean & n=6 for obese). None of the changes reached statistical significance because of high individual variation. (E) Comparison of urine albumin/creatinine ratio to nephrin/actin ratio (C) in Zucker lean and obese rats reveals that the obese rats with highest albuminuria (> 15 mg/mg) express less nephrin in the glomeruli than the obese rats with low albuminuria (< 15 mg/mg). Data are mean ± SD (n=3 for lean, n=2 for obese with low alb/cre, n=4 for obese with high alb/cre). * ≤ 0.05.
using the graded sieving method [2]. Cells were lysed in Nonidet P-40 (NP-40) lysis buffer (1% NP-40, 20 mM HEPES, pH 7.5, 150 mM NaCl) supplemented with 50 mM NaF, 1 mM Na3VO4 and 1 × Complete Proteinase Inhibitor Cocktail (Roche, Basel, Switzerland) at 4 °C for 30 min. Detergent-insoluble material was removed by centrifugation (16,000g at 4 °C for 15 min).
2.2. Quantitative Western blotting

75 μg of glomerular lysates were separated on a 10% SDS-PAGE gel, transferred to PVDF-FL membranes (Millipore, Billerica, MA) and blocked with Odyssey blocking buffer (LI-COR, Lincoln, NE, USA) diluted 1:1 with phosphate buffered saline (PBS). The membranes were incubated with mouse anti-active β -catenin (Millipore, Darmstadt, Germany), mouse anti-desmin 37EH11 [3], rabbit anti-fibronectin (Abcam, Cambridge, UK), guinea pig anti-nephrin (Progen Biotechnik,Heidelberg, Germany), rabbit anti-ZO-1 IgG (Zymed Life Technologies, San Francisco, CA, USA), sheep anti-FOXC2 (R&D Systems, Minneapolis, MN, USA) and rabbit anti-actin (Abcam) IgGs, followed by Alexa Fluor
Treatment of cultured human podocytes with obesity- and diabetes-associated factors

Conditionally immortalized human podocytes (AB8/13) were cultured as described in Datta et al. [1]. Differentiated podocytes were serum starved for 12 h in medium supplemented with 1% fetal bovine serum (FBS) and independently treated with 10 ng/ml TNF-α (R&D Systems) for 2–24 h, 4 ng/ml TGF-β (R&D Systems) for 3 or 6 days, 1 μM angiotensin II (Sigma-Aldrich, St. Louis, MO, USA) for 24 h, or 20 mM glucose (Sigma-Aldrich) together with 200 μM palmitate (Sigma-Aldrich) for the last 7 days of the differentiation period. Sodium palmitate was conjugated with fatty acid-free low endotoxin BSA (Sigma-Aldrich) as described earlier [4]. Solvent only was used as a control for all treatments. Cells were either lysed and immunoblotted as described above or used for preparation of total RNA and quantitative RT-PCR as described below.

2.3. Total RNA preparation and quantitative RT-PCR

Total RNA was isolated, treated with DNase I and reverse transcribed into complementary DNA (cDNA). The quantitative PCR was performed using TaqMan gene expression assays (Applied Biosystems, Foster City, CA) for hFOXC2 (Assay ID: Hs00270951_s1) and hGAPDH (glyceraldehyde 3-phosphate dehydrogenase; Assay ID: Hs99999905_m1) as in [5]. Measurements were performed in triplicate using an iCyclerIQ (BIO-RAD, Hercules, CA, USA). The expression levels of FOXC2 mRNA were normalized to GAPDH using the comparative Ct method (DDCt).

2.4. Quantification of G-actin and F-actin

FOXC2 was lentivirally overexpressed in differentiated human podocytes as described in Datta et al. [1]. The G-actin and F-actin quantification in FOXC2 and control vector-transduced podocytes was performed as described in the G-actin/F-actin in vivo Assay Kit (Cytoskeleton Inc., Denver, CO, USA). Briefly, cells were lysed in a detergent-based lysis buffer that stabilizes and maintains the G- and F- forms of cellular actin. This was followed by a 100,000g centrifugation at 37 °C for 1 h that pellets the F-actin and leaves the G-actin in the supernatant. Samples of supernatant and pellet were separated by SDS-PAGE and actin was quantified by Western blotting using the rabbit polyclonal anti-actin antibody provided in the kit.

2.5. Statistical analysis

Results are presented as mean ± SD. Statistical analysis was performed using Student’s t test (Microsoft Excel, Redmond, WA).
Acknowledgments

This study was supported by the European Research Council (242820; SLe), the Academy of Finland (131255, 218021, 255551; SLe), the Sigrid Jusélius Foundation (SLe), the Päivikki and Sakari Sohlberg Foundation (SL and SLe), the Diabetes Research Foundation (SLe) and the Faculty of Medicine, University of Helsinki (SLe). We thank Prof. Enerbäck (University of Gothenburg, Gothenburg, Sweden) for the FOXC2 construct in pCDNA3.1Hyg. Niina Ruoho (University of Helsinki, Helsinki, Finland) is acknowledged for technical support.

References